Your new experience awaits. Try the new design now and help us make it even better

CASE REPORT article

Front. Med.

Sec. Dermatology

Volume 12 - 2025 | doi: 10.3389/fmed.2025.1670091

This article is part of the Research TopicExploring Innovative Therapies for Rare Inflammatory Skin DiseasesView all 19 articles

Case Report: Pediatric Palisaded Neutrophilic and Granulomatous Dermatitis without Systemic Diseases Treated with Sulfasalazine

Provisionally accepted
Qiuyang  GuoQiuyang Guo1,2,3Yumeng  WangYumeng Wang1,2,3Qiuyi  HanQiuyi Han1,2,3Jinxiang  YangJinxiang Yang1,2,3Jiayan  ZhangJiayan Zhang1,2,3Guofang  LiGuofang Li1,2,3Yijun  YangYijun Yang1,2,3Ruhong  ChengRuhong Cheng1,2,3*Zhirong  YaoZhirong Yao1,2,3*
  • 1Dermatology Center, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
  • 2Department of Dermatology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
  • 3Institute of Dermatology, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, China

The final, formatted version of the article will be published soon.

Abstract: Palisaded neutrophilic and granulomatous dermatitis (PNGD) is a rare neutrophilic dermatosis strongly associated with systemic conditions. Pediatric cases with exclusive cutaneous involvement are exceptionally rare. Current treatment options for PNGD include oral dapsone, hydroxychloroquine, and intralesional or systemic corticosteroids. Here we report a 6-year-old girl with skin-limited PNGD, presenting symmetric annular plaques on limb extensor surfaces and atypical lesions on the face, palms, and buttocks. Significant lesion resolution was achieved after two months of oral sulfasalazine therapy (25 mg/kg/day in divided doses), with only mild abdominal discomfort. To our knowledge, this represents the first successful use of sulfasalazine for PNGD, providing a dapsone-sparing alternative for pediatric PNGD.

Keywords: palisaded neutrophilic and granulomatous dermatitis, neutrophilic dermatosis, Sulfasalazine, pediatric, cutaneous-limited

Received: 21 Jul 2025; Accepted: 16 Oct 2025.

Copyright: © 2025 Guo, Wang, Han, Yang, Zhang, Li, Yang, Cheng and Yao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Ruhong Cheng, shirleywo6@163.com
Zhirong Yao, yaozhirong@xinhuamed.com.cn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.